Evidence Hub

Exploring the mechanism of Polygonum Cuspidatum in the treatment of ischemic stroke by network pharmacology analysis and experimental validation

Cao X, Zhang S, Mao M, Zhang Q, Guo Y

Fitoterapia, 2025

Abstract

Polygonum cuspidatum (PC), a traditional Chinese medicine, has been employed in the treatment of ischemic stroke (IS), yet its precise mechanisms of action remain to be elucidated. This study integrates network pharmacology with in vitro and in vivo experiments to investigate the underlying mechanisms of PC in the treatment of IS. The active components of PC in rat serum samples were identified using ultra-high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS). The active ingredients and mechanism of PC were predicted by network pharmacology. Interactions between key active compounds and major targets were validated through molecular docking. Finally, the efficacy and mechanism of PC in the treatment of IS were verified through in vivo and in vitro experiments. A total of 43 active components of PC were identified, along with 142 targets associated with IS. KEGG analysis suggested that the PI3K/Akt signaling pathway may play a key role in PC's regulation of IS-related injury. Molecular docking confirmed that quercetin, resveratrol, apigenin, luteolin, and torachrysone, may potentially interact with core targets including AKT1, IL6, TNF, TP53 and EGFR. Additionally, we confirmed that PC significantly inhibited the release of inflammatory cytokines and upregulated the phosphorylation of the PI3K/Akt signaling pathway in vitro. In vivo experiments further validated its protective effects. We speculate that this protective…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free